Antimalarial potential of curcumin derivatives evaluated through experimental and computational approaches Authors: Siti Nur Hidayah Jamil, Khairul Azreena Bakar, Amatul Hamizah Ali, Nur Fatin Najihah Marzuki, Fatima Shahid, Fauze Mahmud, Shevin Rizal Feroz, Su Datt Lam, Natsuhisa Oka, Yusmazura Zakaria, Muhamad Imam Muhajir, Rani Maharani, Unang Supratman, Jalifah Latip Published: 2025 ABSTRACT AbstractMalaria remains a leading global health threat, with cases and deaths continually increasing each year. The rising number of drug-resistant cases further diminishes the effectiveness of current antimalarials, highlighting the need for potent and effective new compounds. Curcumin, a natural polyphenol, has been extensively studied for its therapeutic properties. However, its clinical use is limited by poor bioavailability. This study evaluates curcumin derivatives as potential antimalarial agents through in-silico screening and biological assessments, aiming to identify promising candidates for further development. For the first time, we reveal the multi-target mechanisms of action of these derivatives, focusing on their potential for immunomodulatory GSK-3β inhibition and haemin binding. The ten synthesised compounds, which include Knoevenagel condensates, heterocyclic pyrazoles, and monocarbonyl derivatives, show favourable GSK-3β binding and improved specific ADMET parameters compared to curcumin, along with favourable electronic and reactivity profiles. These compounds also demonstrate greater potency than curcumin against both P. falciparum CQ-sensitive 3D7 and multidrug-resistant K1 strains. Notably, monocarbonyl derivative 20 exhibited the most potent EC50 (0.15 ± 0.03 µM for 3D7 and 2.53 ± 1.06 µM for K1), with selective in vitro inhibition of GSK-3β. Most compounds, apart from pyrazole derivatives 17–18, showed higher cytotoxicity potential. Additionally, ITC experiments indicated that curcumin derivatives can spontaneously bind haemin thermodynamically, which may contribute to their increased activity in pLDH assays. Overall, these findings highlight the multifaceted biological potential of structurally derived curcumin compounds for antimalarial development. This research exemplifies efforts to address the urgent need for potent antimalarials capable of overcoming parasite resistance.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-32346-7.Keywords: Curcumin derivatives, Antimalaria, GSK-3β, Antiplasmodial, Isothermal titration calorimetry (ITC), DFT calculationsSubject terms: Chemistry, Computational biology and bioinformatics, Drug discovery Introduction The global infection rate of malaria is estimated to have reached 263 million in 2023, covering 84 malaria-endemic countries, with a fatality rate of 13.7 per 100,000 population and an estimated 597,000 deaths1. First identified in 1880, malaria is caused by Plasmodium parasites, mainly P. falciparum and P. vivax, infecting humans. These parasites are transmitted by female Anopheles mosquitoes and can enter the circulatory system within 30 min after a bite2,3. The parasites first target liver cells and erythrocytes, and if the affected individual remains untreated, the infection could develop into deadly haemorrhagic conditions, including severe and cerebral malaria, which involve parasite invasion into the brain and immune system. Although much progress has been achieved towards eliminating malaria, the recent rise in malaria cases, particularly in Southeast Asia, is alarming1,4. For example, approximately 17,125 cases have been reported in Malaysia over a period of only four years (2017–2021). In addition to the growing number of malaria cases, the Plasmodium parasites resistance against current antimalarial drugs such as artemisinin and chloroquine (CQ) is highly concerning. Therefore, the development of effective antimalarial and anti-inflammatory agents is crucial for curbing and eradicating malaria across the globe. The current search for novel antimalarials has mainly revolved around natural compounds, including curcumin. Curcumin, a polyphenol from the rhizomatous perennial plant Curcuma longa (turmeric) as shown in Fig. 1, is an attractive potential antimalarial owing to its proven effectiveness as a traditional therapeutic. It is acknowledged by the US Food and Drug Administration (FDA) as “generally recognised as safe” (GRAS) and is non-toxic even at high doses5–7. Curcumin has been documented to exhibit a wide array of pharmacological activities, including antimicrobial, antitumour, antioxidant, anti-inflammatory, and antiprotozoal activities by regulating various biological responses in the body8,9. Therefore, it has emerged as a desirable lead compound with dual antimalarial and anti-inflammatory properties for the development of new antimalarial agents10. 2D and geometry optimised 3D structures of the keto-isomer of curcumin. Its antimalarial activity was first reported by Reddy et al.11 based on in vitro and in vivo assessments, which showed potent growth inhibition of CQ-resistant P. falciparum (IC50: ~5 µM) and reduction of blood parasitaemia level by 80–90% upon treatment of P. berghei-infected mice with curcumin over three weeks. Nevertheless, the low bioavailability of curcumin, due to rapid metabolism, poor oral absorption, and low aqueous solubility, is a major limiting factor for its clinical applications. Prior studies have explored the use of adjuvants, nanoencapsulation, and structural modifications of curcumin to enhance its pharmacological properties12,13. Among these strategies, the synthesis of curcumin derivatives is seen as advantageous, potentially producing analogues with enhanced biological activity whilst maintaining the safety profile. While the Plasmodium parasite is the root cause of malaria infection, the escalation of the more severe malaria infection is partly attributed to complications arising from dysregulated immune responses in humans, which have heightened the mortality rates. This immune response primarily involves the modulation of pro- and anti-inflammatory cytokine levels. Human glycogen synthase kinase 3 (GSK-3β) is a serine-threonine kinase immunomodulatory protein involved in the host immune response in malaria infection. It is recognised as a novel target for antimalarial drugs due to its involvement in the dysregulated PI3K/Akt signalling triggered by the invasion of Plasmodium parasites (Fig. 2). Inhibiting GSK-3β was proven, in vivo, to mediate antimalarial effects in humans based on the improved median survival time for infected mice, a reduction in pro-inflammatory cytokine levels, and elevated anti-inflammatory cytokines10. Therefore, the potential of curcumin and its derivatives as GSK-3β inhibitors in regulating inflammatory cytokine levels complements their potential as antimalarial agents, presenting an effective avenue to impede the progression of malaria to more severe stages. Signalling pathway involved in the mechanism of action of curcumin and its derivatives, which inhibit GSK-3β, leading to the regulation of pro- and anti-inflammatory cytokine levels. Hence, our research explored curcumin derivatives with potential dual antimalarial and anti-inflammatory activities. Specifically, Knoevenagel condensate, heterocyclic pyrazole and monocarbonyl curcumin derivative compounds were screened, in-silico, through molecular docking, molecular dynamics and DFT geometry optimisation assessments to explore and characterise the binding conformations, electronic properties and reactivity profiles. An in-silico approach in early-stage drug discovery is favoured for its time- and cost-effectiveness, and helps justify experimental preclinical studies that are often laborious and costly. The molecular docking and molecular dynamics (MD) simulations demonstrated intermolecular interactions between curcumin derivatives and GSK-3β, while DFT calculations provided insights into the molecular and electronic properties of the compounds. Furthermore, selective compounds with excellent in-silico profiles were synthesised and investigated for their in vitro antiplasmodial activities against P. falciparum 3D7 and K1 strains, ITC haemin binding and yeast-based GSK-3β inhibition, further validating our computational findings. Overall, our current study provides the groundwork for a deeper understanding of the potential of curcumin derivatives as effective antimalarial and anti-inflammatory agents. Results and discussion Structure-activity relationship (SAR) analysis of curcumin derivatives Based on the proven antimalarial and anti-inflammatory activities of curcumin10,11, we have previously performed a literature-based exploration of curcumin derivatives with enhanced bioavailability and bioactivity as potential antimalarial agents19. Previous studies on Knoevenagel condensate, pyrazole, and monocarbonyl derivatives of curcumin have presented their ability to target several proteins involved in malarial infection, including the ATP620, NF-κβ21, PfGCN521 and PfDXR22 proteins. In the present study, we examine the multi-target potential of these curcumin derivatives by analysing their interactions with three different malaria-related targets: Plasmodium lactose dehydrogenase (pLDH), GSK-3β and haemin. The presence of the methoxy phenol group was identified as essential for antimalarial potency of curcumin, as supported by the work of Dohutia et al. and Mishra et al.20,21. Their work showed that the in vitro IC50 of a dimethoxy-substituted phenyl was two-fold higher than that of curcumin, indicating the decreased potency of the derivative. We previously discussed that the design of curcumin derivatives for compounds with improved bioactivity is favoured on the modification of methylene and dicarbonyl groups as they are the most reactive, hence unstable, sites of curcumin19. The design of the Knoevenagel condensate, heterocyclic pyrazole and monocarbonyl derivatives was previously focused mainly on improving the antimalarial activity of curcumin against P. falciparum, rather than its potential as an anti-inflammatory agent (Fig. 3). In this work, among the list of initially selected derivatives, 21 of them were screened and relisted as derivatives with good SAR (Fig. 4) for further molecular docking studies to immunomodulatory GSK-3β protein as the target. Further screening subsequently synthesised and biologically assessed selective promising compounds for their multi-target antimalarial potentials. Structural identity of curcumin showing the modification sites, followed by the three different approaches used for its structural derivatisation. Chemical structures of screened curcumin derivatives with good SAR profiles. In-silico assessments Docking of curcumin derivatives to GSK-3β In searching for and designing compounds with potential inhibitory action against a target protein, molecular docking simulations serve to predict and characterise the interaction between the designed compounds and the amino acids of the target protein. Here, docking simulations were employed to establish an understanding of the anti-inflammatory effect of curcumin derivatives through their interaction with GSK-3β. GSK-3β is identified as a key evolutionarily conserved Ser/Thr kinase involved in the dysregulation of PI3K/Akt signalling, triggered by the invasion of Plasmodium parasites. Hence, inhibiting GSK-3β is essential for managing advanced malarial infections, including cerebral and severe malaria14,15. The function of GSK-3β is highly dependent on the hinge region containing conserved residues such as Asp133 and Val135 that make up an essential part of the ATP-binding pocket16. This facilitates the catalytic activity of GSK-3β, leading to the production of pro-inflammatory cytokines through NF-κB activation. The binding of an inhibitor ligand to GSK-3β will cause a conformational change, preventing access of its substrate to the active site17, thus suppressing NF-κB and ultimately promoting anti-inflammatory responses14,18. The ligand originally bound to the 1Q5K crystal structure of GSK-3β, TMU1 (AR-A014418), is a potent and selective GSK-3β inhibitor that attenuates the inflammatory response23,24. Hence, TMU1 was re-docked for docking-site validation24,25. The cross-docking validated the docking cavity and coordinates used for the molecular docking simulation with a binding energy of − 6.451 kcal/mol and an RMSD value of 0.491 Å. Further, the binding cavity of GSK-3β was defined by the residues involved in the TMU1–GSK-3β binding: Ile62, Val70, Ala83, Tyr134, and Val135, as illustrated in Fig. 5. Comparison between the co-crystallised and the re-docked TMU1 within the binding site of GSK-3β showing similar conformation and docked position with a favourably low RMSD (0.491 Å). Curcumin 1 and its derivatives were hypothesised to bind to the same binding site as TMU1. Indeed, as shown in Table 1 and depicted in Supporting Information S1–S2, curcumin exhibited favourable affinity towards GSK-3β and was docked to the same binding pocket as TMU1 based on the residues involved in the interaction. In contrast to TMU1, curcumin formed a more extensive network of hydrogen bonding involving five residues: Asp133, Tyr134, Arg141, Asn186, and Cys199, resulting in a stronger binding energy of − 7.437 kcal/mol. Table 1Curcumin derivatives categorised according to the type of structural modification and the affinity towards GSK-3β.CompoundBinding energy, kcal/molType of interactionAmino acid residues involved in bindingTMU1-–6.451Hydrogen bondsVal135Hydrophobic interactionsIle62, Val70, Ala83, Tyr134Curcumin 1 –7.437Hydrogen bondsAsp133, Tyr134, Arg141, Asn186, Cys199Hydrophobic interactionsIle62, Val70, Ala83, Leu188Knoevenagel condensate derivatives 2 –8.772Hydrogen bondsIle62, Val135, Arg141, Cys199Hydrophobic interactionsIle62, Val70, Ala83, Lys85, Val110, Leu132 3 –9.424Hydrogen bondsIle62, Asp133, Tyr134, Pro136, Arg144. Cys199Hydrophobic interactionsIle62, Val70, Ala83, Lys85, Lys183, Leu188, Cys199 4 –9.070Hydrogen bondsVal62, Arg141, Asp133Hydrophobic interactionsIle62, Gly63, Val70, Ala83, Leu132, Leu188, Cys199 6 –9.079Hydrogen bondsIle62, Lys85, Tyr134, Val135, Arg141, Cys199Hydrophobic interactionsIle62, Val70, Ala83, Lys85, Val110, Leu132, Tyr134 10 –10.310Hydrogen bondsAsp133, Tyr134, Val135, Arg141, Arg144Hydrophobic interactionsIle62, Val70, Ala83, Tyr143, Leu188Electrostatic interactionsArg141Pyrazole derivatives 17 –8.728Hydrogen bondsVal61, Tyr134, Arg144, Asp200Hydrophobic interactionsIle62, Ala83, Lys85, Val110, Leu132, Leu188, Cys199Electrostatic interactionsArg141 18 –8.093Hydrogen bondsCys199, Asp200Hydrophobic interactionsIle62, Gly63, Val70, Lys85, Val110, Leu132, Leu188Electrostatic interactionsArg141Monocarbonyl derivatives 20 –8.161Hydrogen bondsTyr134, Val135, Arg141, Asn186Hydrophobic interactionsIle62, Val70, Lys85, Cys199 21 –8.100Hydrogen bondsIle62, Arg141 Val135, Asp200Hydrophobic interactionsIle62, Val70, Ala83, Val110, Leu132, Leu188, Cys199 22 –8.970Hydrogen bondsIle62, Try134, Arg144, Asp200Hydrophobic interactionsIle62, Val70, Ala83, Val110, Leu132, Leu188, Cys199 Curcumin derivatives categorised according to the type of structural modification and the affinity towards GSK-3β. The docking simulations were repeated with the aforementioned 21 curcumin derivatives, out of which ten derivatives showed better binding profiles compared to curcumin (Table 1 and S1–S5). All derivatives demonstrated stronger inhibition, reflected by the more negative binding energies compared to curcumin. For some of the compounds (derivatives 10, 17 and 18), the interactions not only involved hydrogen bonds and hydrophobic interactions, but also featured a pi-cation electrostatic interaction involving Arg141. These differences in binding characteristics likely contributed to the enhanced affinity for GSK-3β. Similarly, derivatives 3 and 6 also showed better interactions with GSK-3β than the parent curcumin, with binding energies of − 9.424 and − 9.079 kcal/mol, respectively. Notably, these derivatives potentially benefited from stronger hydrophobic interactions involving six residues, compared to only five for curcumin. As for the heterocyclic pyrazole derivatives, compounds 17 and 18 also exhibited higher binding energies than curcumin (–8.728 and − 8.093 kcal/mol, respectively), revealing the significant contribution of hydrophobic interactions, in addition to the hydrogen bonds, in stabilising their complexation with GSK-3β. Likewise, the monocarbonyl derivatives 20, 21 and 22 were identified to bind more favourably to GSK-3β than curcumin (binding energies: − 8.161, − 8.100 and − 8.970 kcal/mol, respectively). Our comparative molecular docking revealed that all three derivatisation strategies produced compounds with better binding profiles over curcumin towards GSK-3β and thus, potentially higher inhibitory activity against the protein. Therefore, these ten derivatives (Knoevenagel condensates 2–4, 6 and 10, heterocyclic pyrazoles 17 − 18, and monocarbonyls 20–22) were selected for MD simulations and DFT calculations. MD analysis To further validate the docking results, MD simulations, which allow a deeper understanding of the stability, structural and conformational fluctuations, and kinetic behaviour of ligands and proteins upon their binding, were performed. The simulation creates a dynamic environment in which molecular interactions would happen as in the cellular milieu. The conformational changes of the ligand-protein complexes can be observed and analysed for a particular time scale to compare the stability of the different complexes. The simulation environment mimics the biological conditions to assess ligand-protein stability, while allowing conformational changes of the ligand within the active site of the protein26. In this study, MD simulations of the binding of curcumin and the ten derivatives to GSK-3β were carried out over 100 ns to generate information on root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), and hydrogen bond interactions. To highlight and validate the docking results, which converged to derivative 10 as the top hit ligand with the highest binding affinity, RMSD plots were generated as shown in Fig. 6. RMSD information (Figs. 1 and 6(a), 1(b), 1(a)-ligand and 1(b)-ligand) presents the stability of a compound to stay within its docked conformation and maintain its binding throughout the simulation time26. The RMSD of the complexes for curcumin started at 0.1 nm and stabilised within the range 0.4–0.7 nm after 10 ns, while derivative 10 started at 0.1 nm and stabilised within 0.3–0.4 nm after 25 ns through the whole simulation period, indicating less conformational deviation than curcumin. In addition, based on the plots of ligand-RMSD as presented in Figs. 1 and 6(a)-ligand and 1(b)-ligand, the same graph trend is observed compared to the complexes. This shows that the detected movement of the complexes throughout the simulation is based on the movement of both ligand and protein, with RMSD of derivative 10 showing a less deviated range of RMSD (0.25–0.35 nm) after it stabilised at 5 ns (1(b)-ligand), compared to curcumin with larger RMSD range (0.15–0.45 nm). Hence, this validates the stability of the ligand, specifically derivative 10, to retain its docked configuration within the binding cavity of GSK-3β. Analysis of MD simulations of ligand-GSK-3β complexation involving curcumin 1 (1–4(a)) and derivative 10 (1–4(b)). The RMSF plots (Figs. 2 and 6(a) and 2(b)), which illustrate the flexibility and fluctuations of particular residues during the simulations27, show that curcumin, with RMSF values ranging between 0.05 and 0.40 nm, fluctuates more than 10, with RMSF values ranging between 0.05 and 0.35 nm. These fluctuations could be influenced by the conformational changes adopted by the residues, to facilitate ligand binding27. Notably, there are fluctuations observed involving the Ile62, Val70, and Ala83 which signifies the hydrophobic interactions (Table 1), and residues Asp133, Tyr134, and Val135 which reasoned the hydrogen bonding interactions. Additionally, the highest fluctuation at 0.35 nm RMSF is observed at residue Ser219, which is one of the catalytic residues that might also influence significant dynamics of the protein. Further, the hydrogen bonds involving Asp133, Tyr134, Val135, Arg141, Arg144 residues are also maintained (Figs. 3 and 6(b)) as the observed number of hydrogen bonds was retained between two to four throughout the MD simulation for the derivative 10-GSK-3β complex, which is more than that observed for the curcumin-GSK-3β complex. This suggests that derivative 10 is more stable while maintaining the hydrogen bonds and, hence, holds stronger interactions with GSK-3β. The gyration plots (Figs. 4 and 6(a) and 4(b)) explain the spatial distribution or compactness of the complexes. The gyration for curcumin projected highly variable and fluctuating trends on the plots with values ranging from 2.112 to 2.185 gyration, compared to derivative 10, which maintains a consistent and stable range of gyration between 2.115 and 2.180. Hence, this indicates that the derivative 10-GSK-3β complex is more compact than curcumin. Based on these, derivative 10 is justified as the top-hit compound with the highest probability for binding and dynamically stable in maintaining its ligand-protein structure, hence validating the molecular docking results. ADMET assessment Further, the pharmacokinetic properties of these compounds, characterised by their predicted ADMET profiles, are presented in Table 2. The in-silico assessment included selective parameters such as the topological polar surface area (TPSA), pan-assay interference compounds (PAINS), water solubility, intestinal absorption, blood-brain-barrier (BBB) and central nervous system (CNS) permeability, total clearance, and toxicity. Table 2Predicted ADMET profiles of Curcumin (1) and its derivatives.Compound12346101718202122Molecular weight, g/mol368.38456.49472.49502.51472.49501.48485.49509.38326.34352.38366.41 H-bond acceptor 66787875555 H-bond donor 22333222222Log Pa, log (mol/L)–4.356–6.247–5.159–5.440–4.897–5.721–4.889–5.380–4.137–4.480–4.643TPSAab, Ų93.0693.06113.29122.52113.29138.88122.5676.7475.9975.9975.99 PAINS alert 00000000011 ABSORPTION c Log S, log (mol/L)–4.450–6.570–5.980–6.080–5.980–5.900–6.460–8.290–4.120–5.090–5.370Intestinal absorption, %75.49484.34776.0770.18676.13781.14597.63688.88593.61392.74892.114 DISTRIBUTION BBB permeability, log (mol/L)–0.528–0.606–1.024–1.316–1.14–1.128–1.098–0.957–0.221–0.158–0.152CNS permeability, log (mol/L)–2.964–2.975–2.937–3.096–2.976–2.968–2.208–1.759–2.377–2.078–1.984 METABOLISM d CYP2D6/CYP3A4 substrate No/YesNo/YesNo/YesNo/YesNo/YesNo/YesNo/YesNo/YesNo/NoNo/NoNo/No CYP2D6/CYP3A4 inhibitor No/YesNo/YesNo/YesNo/YesNo/YesNo/YesNo/YesNo/YesNo/YesNo/YesNo/Yes CYP1A2 inhibitor NoNoNoNoNoNoNoNoYesYesYes CYP2C19/CYP2C9 inhibitor Yes/YesYes/YesYes/YesYes/YesYes/YesNo/YesYes/YesYes/YesYes/YesYes/YesYes/Yes EXCRETION Total Clearance, log (mL/min/kg)0.0710.0420.0020.0160.0200.0700.2090.2220.0910.1140.122 Renal OCT2 substrate NoNoNoNoNoNoNoNoNoNoNo TOXICITY MTRDe (human)0.510.110.190.010.16–0.180.270.420.450.210.20 AMES toxicity NoNoNoNoNoNoNoNoNoNoNo Hepatotoxicity NoNoNoNoNoNoNoYesNoNoNo Cytotoxicity NoNoNoYesNoNoNoNoNoNoNoa The optimal range of lipophilicity (log P) is generally between 0 and 3.b Lower TPSA value is preferred for better cell permeability and oral bioavailability: < 90 Å2: Good, 90–140 Å2: Moderate, > 140 Å2: Poor. c Intestinal absorption: good if > 30%. d Being a non-substrate and inhibitor means slower metabolism. e MTRD is predicted to be low if ≤ 0.477, or high if > 0.477. Predicted ADMET profiles of Curcumin (1) and its derivatives. a The optimal range of lipophilicity (log P) is generally between 0 and 3. b Lower TPSA value is preferred for better cell permeability and oral bioavailability: < 90 Å2: Good, 90–140 Å2: Moderate, > 140 Å2: Poor. c Intestinal absorption: good if > 30%. d Being a non-substrate and inhibitor means slower metabolism. e MTRD is predicted to be low if ≤ 0.477, or high if > 0.477. The TPSA values for most of the assessed derivative compounds are within the range for moderate cell permeability and oral bioavailability (90–140 Ų), except for derivatives 18, 20, 21 and 2220,28. In addition, PAINS moieties were also assessed to identify compounds that tend to be false positives based on promiscuous structural features29. Two of the derivatives, 21 and 22, showed an alert for PAINS, which may suggest that these compounds are associated with potential false positive results. Furthermore, achieving adequate bioavailability is crucial for effective pharmacological action30,31. The predicted lipophilicity values (log P) for all derivatives were beyond the optimal range. While these values are generally considered acceptable for drug-like properties according to the Lipinski’s rule of five (log P < 5), this suggests potential challenges for optimal solubility and permeability. Next, with the exception of derivative 20, the predicted water solubility (log S) for all derivatives was, however, lower than that of curcumin. Hence, these derivatives might have a lower rate of dissolution and absorption into the bloodstream. Nevertheless, the derivatives were predicted to have favourable intestinal absorption with values above 70%. Thus, sufficient concentrations of these compounds are expected to reach the systemic circulation to exert therapeutic effects. With regard to the blood-brain barrier (BBB) and central nervous system (CNS) permeabilities of the derivatives, there appeared to be no major changes upon structural modifications to the parent curcumin. Despite variations in the values of log BB (blood-brain barrier penetration) and log PS (permeability-surface area product), all tested compounds were classified as unable to readily cross the BBB and penetrate into the CNS. Hence, it is expected that the derivatives would not cause neurologically related side effects. Another factor limiting curcumin’s bioavailability is its rapid excretion, which reduces its effective duration of action. As shown in Table 2, the total clearance of the Knoevenagel condensate derivatives was lower than that of curcumin, signifying potentially slower excretion and longer in vivo availability. Additionally, all compounds were predicted to be non-substrates of the renal OCT2, which is responsible for compound uptake to renal cells. Thereby, the derivatives were expected to be less rapidly excreted, leading to slower clearance, and less likely to be accumulated in renal tubular cells, hence reducing the risk of nephrotoxicity32. Finally, the toxicity predictions performed include maximum tolerated dose (MTRD), Ames toxicity (mutagenicity), hepatotoxicity (liver-associated side effects), and cytotoxicity (cell disruptability). Non- or low toxicity is a critical requirement in ensuring the safety of a drug candidate to mitigate potential risks of adverse effects. Thus, it should be noted that all derivatives were predicted to have lower MTRD as opposed to curcumin, whereby those compounds could be toxic at higher doses, while derivatives 4, 10 and 18 also potentially exhibit toxicity, which should be taken into consideration for further drug development33. Geometry optimisation by DFT calculations DFT calculations revealed that the derivatives generally maintained a stable molecular structure and possessed improved molecular and electronic properties, suggesting enhanced chemical reactivity and stability. It has been suggested that the geometry and charge distribution of a molecule, comprising the molecular orbital (MO) descriptors including molecular structure energy E, HOMO, LUMO, and dipole moment (Table 3 and S6–S8), are important factors affecting the biological activities of a compound34,35. In addition, the DFT results also provide the reactivity analysis based on the global reactivity parameters, including ionisation potential IP, electron affinity EA, chemical potential µ, electronegativity , chemical hardness η and electrophilicity index ω36–39, in which the corresponding information is presented in Table 3. To specifically understand the reactivity of the derivative compounds as potential drug candidates with optimal pharmacokinetics and bioavailability40, these parameters are investigated in comparison with the parent curcumin. Applying DFT calculations to identify the lowest energy geometry of curcumin derivatives rationalises their ability to form molecular interactions with GSK-3β. Table 3Molecular structure energy E, dipole moment, molecular orbital energy gap and the global reactivity parameters of Curcumin and selected derivatives obtained from DFT calculations.CompoundE, a.u.Energy gap, eVDipole moment, DebyeIP, eVEA, eVµ, eVη, eVꭓ, eVω, eV Curcumin –1263.643.59906.07925.99472.3957–4.19521.79954.19524.8901 2 –1532.813.61863.90735.93292.3143–4.12361.80934.12364.6991 3 –1608.033.61454.80045.89262.2781–4.08541.80724.08544.6176 4 –1722.553.39845.49085.78982.3913–4.09061.69924.09064.9236 6 –1608.033.61075.22265.97812.3674–4.17271.80534.17274.8223 10 –1683.263.19166.69066.14652.9549–4.55071.59584.55076.4885 17 –2373.501.98131.91543.75351.7723–2.76290.99062.76293.8529 18 –1553.532.49773.79805.48502.9873–4.23611.24894.23617.1844 20 –1111.003.41757.61975.82622.4088–4.11751.70874.11754.9609 21 –1187.203.30464.67165.43982.1353–3.78761.65233.78764.3412 22 –1227.743.45564.99245.68612.2305–3.95831.72783.95834.5342 Molecular structure energy E, dipole moment, molecular orbital energy gap and the global reactivity parameters of Curcumin and selected derivatives obtained from DFT calculations. The Knoevenagel condensate and heterocyclic pyrazole derivatives, particularly derivatives 4, 10, and 17, possessed favourably more negative molecular structure energy compared to curcumin (Table 3), indicating that these specific derivatives are more structurally stable than curcumin and the monocarbonyl derivatives. Similarly for IP and EA, except for derivative 17, the values are very comparable to curcumin, which signifies the effectiveness and degradability, where these compounds are expected to remain stable against oxidation processes. The frontier MO analysis based on the HOMO-LUMO energy gap allows for the evaluation of the chemical reactivity of a compound. As shown in Table 3 and S6, derivatives 10 and 17 have smaller energy gaps with values lower than 3.2 eV and higher electrophilicity index ω, suggesting that these compounds would possess higher binding potential and more readily interact with target proteins. Further, the slightly more negative value of chemical potential µ, specifically for derivative 10, and comparable values for most of the other derivatives, signify the electron and charge distribution of these compounds. Compound 10 with a more negative µ is expected to potentially have better molecular interactions and binding, hence better affinity with the target protein. This agrees with the finding from the molecular docking study, which presented derivative 10 with the highest potential for binding to the target protein. Additionally, the HOMOs and LUMOs also interpreted the electrophilicity of the C and O atoms of the dicarbonyl groups. Based on the HOMOs, the orbitals do not participate in the electron donation, while the LUMOs show that the orbitals are able to accept electrons. This verifies that the carbonyl group is non-nucleophilic but highly electrophilic, hence supporting the rationale of targeting the carbonyl group as the reactive site of curcumin to synthesise new derivatives19,40. Further, the dipole moment, as measured in Debye, explains the overall charge distribution in a molecule. This parameter correlates to polarity, deformability and electronegativity, where a higher dipole moment reflects a more polar and deformable structure, allowing for greater cellular interactions. Among the compounds, only derivatives 10 and 20 have a higher dipole moment than curcumin, and hence, higher polarity and solubility, thus resulting in potentially enhanced bioavailability. However, the electronegativity data showed that all derivatives possessed similar values to curcumin except for derivative 17, suggesting that these compounds have very comparable polarity with curcumin. Further, DFT results also allow for simulating the shelf and thermodynamic stability of these compounds based on the chemical hardness parameter η. Most compounds, specifically the Knoevenagel condensate and monocarbonyl derivatives, have similar η values to curcumin, indicating that these compounds are expected to have good stability and not easily degrade, and this is beneficial for the development of drugs with convenient oral dosage forms and better shelf-life41. Throughout, most derivative compounds generally showed favourable electronic and reactivity profiles, hence supporting their ability to form molecular interactions with GSK-3β. Synthesis of Curcumin derivatives We have previously reviewed the synthesis of several curcumin derivatives (Knoevenagel condensates 2 − 4, 6, 10, heterocyclic pyrazoles 17–18, and monocarbonyl 20)19. The synthesis strategy of the Knoevenagel condensates is relatively straightforward, based on a procedure adapted from previous reports with some modifications42,43. The reaction condition was optimised, including the amount of solvent, catalysts, and experimental conditions, affording high percentage yields of all desired Knoevenagel condensate curcumin derivatives (Scheme 1). The synthesis was performed in one step by reacting curcumin and an excess of respective R-benzaldehyde in DMF, in the presence of acetic acid and piperidine at RT for 48 h, to successfully obtain derivatives 2–4, 6 and 10 in yields between 63 and 79%. The presence of both acid and base catalysts facilitated the reaction by protonating the aldehyde, making it more electrophilic, and deprotonating the highly acidic methylene hydrogen of curcumin, making it more nucleophilic. Despite most published Knoevenagel condensation reactions being done at a higher temperature (> 70℃, reflux) using methanol or ethanol as solvents, the use of DMF as the solvent allowed the reaction to proceed at higher concentrations, lower temperatures and safer conditions. Synthesis of Knoevenagel condensate derivatives (2–4, 6 and 10). R-benzaldehyde: benzaldehyde (2), 4-hydroxybenzaldehyde (3), 4-hydroxy-3-methoxybenzaldehyde (4), 3-hydroxybenzaldehyde (6) and 4-nitrobenzaldehyde (10). The heterocyclic pyrazole derivatives 17 and 18 were synthesised based on published procedures (Scheme 2)21,44. The synthesis was achieved through a one-step procedure by reacting curcumin with an excess of respective R-phenylhydrazine hydrochloride in acid-catalysed ethanolic reaction, at 85℃ (reflux) for 15 h. The presence of acetic acid catalyst protonates the carbonyl group of curcumin, making it more susceptible to nucleophilic attack by the hydrazine and leading to the formation of a hydrazone intermediate. This intermediate then undergoes intramolecular cyclisation, eliminating water and generating the aromatic pyrazole ring, producing the desired compounds in yields in the range 65–70%. Synthesis of heterocyclic pyrazole derivatives (17–18). R-phenylhydrazine hydrochloride: 3-nitrophenylhydrazine hydrochloride (17) and 2,4-dichlorophenylhydrazine hydrochloride (18). The monocarbonyl curcumin derivatives 20–22 were successfully synthesised based on the procedure described by Deck et al. and Du et al.45,46 by total synthesis through aldol reaction between two equivalents of aldehyde and one equivalent of ketone (Scheme 3). Vanillin was reacted with an appropriate ketone in glacial acetic acid saturated with anhydrous concentrated hydrochloric acid, at 30℃ for 2 h to obtain the desired compounds (yield: 61–71%). Synthesis of monocarbonyl curcumin derivatives 20–22. Ketone: acetone (20), cyclopentanone (21) and cyclohexanone (22). Biological activities Antiplasmodial activity and cytotoxicity Antiplasmodial activity of the curcumin derivatives against P. falciparum 3D7 (CQ-sensitive) and K1 (multidrug-resistant) strains, evaluated based on the values of EC50 (effective concentration for 50% inhibition), CC50 (cytotoxicity to WRL-68 human cells), and Selectivity Index (SI) are presented in Table 4 and S20–S32. The EC50 values obtained against both strains suggest the potential inhibition of parasite metabolism, particularly through the interference with pLDH, a crucial enzyme involved in the glycolytic pathway of the parasite. CQ, the reference compound, showed exceptional potency (EC50 = 0.008 µM for 3D7) and high selectivity (SI = 12352 for 3D7). The parent compound, curcumin, was moderately active (EC50 = 8.32 µM for 3D7) and non-toxic to human cells (CC50 > 99 µM) with moderate selectivity (SI = 11.99). Table 4Antiplasmodial activities of Curcumin derivatives against P. falciparum 3D7 (CQ-sensitive strain) and K1 (multidrug-resistant strain), and cytotoxicity against WRL-68 human cells.CompoundEC50 ± SD, µMWRL-68 CC50 ± SD, µMSelectivity Index (SI)aResistance Index (RI)b3D7K13D7K1 CQ 0.008 ± 0.0030.53 ± 0.1298.82 ± 0.212352.50186.4566.25 Curcumin 8.32 ± 2.6230.66 ± 5.44> 9911.903.233.69 2 3.79 ± 0.8817.09 ± 2.330.10 ± 0.020.030.014.51 3 4.35 ± 2.4313.33 ± 7.233.34 ± 1.090.770.253.06 4 1.79 ± 0.3518.84 ± 0.780.31 ± 0.110.170.0210.53 6 1.15 ± 0.2611.01 ± 2.670.19 ± 0.070.170.029.57 10 2.77 ± 0.569.10 ± 1.040.53 ± 0.140.190.063.29 17 0.82 ± 0.3716.70 ± 5.76> 99120.735.9320.37 18 3.29 ± 0.7025.90 ± 0.79> 9930.093.827.87 20 0.15 ± 0.032.53 ± 1.063.93 ± 0.9526.201.5516.87 21 0.25 ± 0.111.47 ± 0.362.16 ± 0.598.641.475.88 22 0.20 ± 0.091.30 ± 0.376.71 ± 1.8233.555.166.50a Selectivity Index (SI) = CC50 MTT/EC50 pLDH. b Resistance Index (RI) = EC50 K1/EC50 3D7. Antiplasmodial activities of Curcumin derivatives against P. falciparum 3D7 (CQ-sensitive strain) and K1 (multidrug-resistant strain), and cytotoxicity against WRL-68 human cells. a Selectivity Index (SI) = CC50 MTT/EC50 pLDH. b Resistance Index (RI) = EC50 K1/EC50 3D7. All assessed derivatives exhibited better activity than curcumin, against both strains, based on the lower EC50 values, with activity against the 3D7 strain being greater compared to the K1 strain. Derivatives 4 and 6 of the Knoevenagel condensate derivative compounds showed better activity against the 3D7 strain, with EC50 values of 1.79 ± 0.35 µM and 1.15 ± 0.26 µM, respectively. In addition, pyrazole derivative 17 also demonstrated significant antiplasmodial activity based on EC50 = 0.82 ± 0.37 µM (3D7) and 16.70 ± 5.76 µM (K1). Meanwhile, monocarbonyl derivatives 20–22 exceptionally exhibited better and more potent activities against both 3D7 (EC50 = 0.15–0.25 µM) and K1 (EC50 = 1.30–2.53 µM) strains, than curcumin. However, the cytotoxicity and SI analysis revealed that most derivative compounds exhibit potential cytotoxicity, whereby pure compounds are classified as toxic to normal mammalian cells when the CC50 value is less than 10 µM or 4 µg/mL47,48. Pyrazole derivatives 17 and 18 are the only derivative compounds that showed no toxicity (CC50 > 99) and SI of 120.73 (3D7) and 5.93 (K1) for 17 and 30.09 (3D7) and 3.82 (K1) for 18. This reinforces the safety profile of these pyrazole derivatives, suggesting their promising potential. Overall, all derivatives showed lower EC50 values against 3D7 compared to K1, and a higher resistance index value (RI > 1), implying a potential resistance factor in multidrug-resistant parasites. This warrants further assessment of the mechanism of action. Throughout, the in vitro evaluation of all synthesised derivative compounds demonstrated promising antiplasmodial activity based on the observed effective concentration EC50 values against both 3D7 and K1 strains, which indicate that all synthesised compounds exhibit significantly better potency, surpassing the parent compound, curcumin. Specifically, monocarbonyl derivatives 20–22, which have smaller MWs, are observed to be much more potent than the other derivatives. Among all derivatives, the findings also highlighted that 17 exhibit the most notable inhibition, a non-toxic and therapeutically more potent antimalarial agent than curcumin and other derivative compounds. Overall, these findings presented the potential of curcumin derivatives for further development as selective antiplasmodial drugs. Yeast-based in vitro GSK-3β Inhibition The study further paved in the attempt to evaluate the potential GSK-3β inhibition of these curcumin derivatives. The inhibition of GSK-3β by curcumin was only recently shown experimentally by Ali et al.10,18, but was earlier suggested through preliminary computational simulations51. While all derivative compounds exhibited more effective inhibition against the pLDH assays (Table 4), the GSK-3β inhibition was only observed for monocarbonyl derivative 20, selectively at 0.02 M, despite in-silico findings demonstrating potential inhibition across all derivative compounds (Table 5 and S35). This discrepancy underscores the complexity of target specificity in the complex biological environment, where factors such as molecular weight, solubility and stability, which are beyond the molecular docking and MD scores, should be taken into consideration. Smaller molecular size/weight and better lipophilicity (logP) of derivative 20 might be influencing the efficacy for better passive diffusion to penetrate the yeast cell membrane52. Curcumin and all other derivative compounds with higher molecular weights and lower log P may struggle to penetrate and effectively interact with GSK-3β within the yeast system, hence, no inhibitory activities were observed. Table 5Inhibition of GSK-3β at 28 ℃ and 37 ℃ Inhibition zones from the yeast-based assay.CompoundConcentration, MZone of inhibition, mmRemarks28 ℃37 ℃ Curcumin 0.0002–0.5--No activity 2 0.0002–0.5--No activity 3 0.0002–0.5--No activity 4 0.0002–0.5--No activity 6 0.0002–0.5--No activity 10 0.0002–0.5--No activity 18 0.0002–0.5--No activity 19 0.0002–0.5--No activity 20 0.57.50 ± 0.718.00 ± 0.00Selective inhibition of GSK-3β at 0.02 M0.057.00 ± 0.008.00 ± 0.000.02-7.00 ± 0.000.002--No activity0.0002--No activity 21 0.0002–0.5--No activity 22 0.0002–0.5--No activity TDZD-8 a 0.0216.67 ± 1.4118.00 ± 1.66Non-selective inhibition of GSK-3β DMSO b –--No activitya positive control. b blank sample. Inhibition of GSK-3β at 28 ℃ and 37 ℃ Inhibition zones from the yeast-based assay. a positive control. b blank sample. Haemin binding activity The potential of binding to haemin, an essential intermediate in the haem detoxification pathway of Plasmodium, is one of the mechanisms of action of antimalarial drugs such as CQ and artemisinin. The haem released from haemoglobin hydrolysis by the malaria parasite is detoxified into the inert hemozoin; hence, interference with this process leads to toxic haemin accumulation and death of the parasite49,50. Strong binding to free haemin can inhibit its detoxification and thus serve as a validated antimalarial mechanism of action, as exemplified by CQ. Therefore, the binding characteristics of the synthesised compounds with haemin were accessed using ITC experiments, elucidating key parameters including the association constant (Ka), binding ratio (n), and changes in enthalpy (ΔH), entropy (ΔS), and Gibbs free energy (ΔG), thereby facilitating a direct comparison with the reference compounds curcumin and CQ (Table 6 and S33–S34). Table 6Thermodynamic properties of the binding of Curcumin derivatives to Haemin from ITC experiments.Compound n Ka × 106, M−1ΔH, kJ/molΔS, J/mol⋅KΔG, kJ/mol CQ 0.47 ± 0.170.14 ± 0.35−37.71 ± 1.12−23.34 ± 0.76−30.48 ± 0.88 Curcumin 0.93 ± 0.124.08 ± 2.64−99.76 ± 0.11−196.05 ± 5.44−38.95 ± 1.80 2 1.27 ± 0.080.23 ± 0.14−99.45 ± 0.55−219.00 ± 7.21−31.52 ± 1.68 3 0.72 ± 0.037.==44 ± 3.48−98.57 ± 1.34−186.75 ± 8.41−40.65 ± 1.26 4 0.39 ± 0.130.35 ± 0.27−94.80 ± 1.56−200.85 ± 1.91−32.52 ± 2.16 6 0.57 ± 0.242.79 ± 1.17−98.08 ± 1.31−212.47 ± 7.56−32.19 ± 1.06 10 0.47 ± 0.010.49 ± 0.32−98.74 ± 0.57−210.50 ± 7.78−33.45 ± 1.85 17 0.55 ± 0.175.44 ± 4.87−99.90 ± 0.08−195.30 ± 9.05−39.34 ± 2.72 18 0.50 ± 0.203.16 ± 1.90−99.11 ± 0.82−196.40 ± 3.70−38.19 ± 1.90 20 0.44 ± 0.151.77 ± 0.73−99.77 ± 0.13−202.45 ± 4.03−36.98 ± 1.10 21 0.52 ± 0.243.27 ± 2.31−98.54 ± 2.06−194.20 ± 0.14−38.31 ± 2.00 22 0.42 ± 0.012.22 ± 2.62−99.42 ± 0.28−199.10 ± 1.83−37.67 ± 0.31 Thermodynamic properties of the binding of Curcumin derivatives to Haemin from ITC experiments. Among the assessed compounds, derivative 3 showed the highest binding affinity to haemin with a Ka of (7.44 ± 3.48) × 10⁶ M⁻¹, approximately 1.8 times higher than curcumin (4.08 ± 2.64) × 10⁶ M⁻¹. Meanwhile, the binding affinities of derivatives 17, 18 and 21 were comparable to curcumin, reflecting favourable interaction strengths. Although derivatives 2, 4, and 10 showed considerably lower Ka compared to other compounds, their binding affinities remain comparable to CQ (10⁵ M⁻¹). Particularly, derivatives 3, 17, 18, and 21 have significant haemin binding affinities, indicating their ability to disrupt the formation of hemozoin and interfere with the detoxification process of the parasite. Further, the nature of the interactive forces involved was determined by analysing the thermodynamic parameters of the interactions (Table 6). All examined binding reactions exhibited negative change in entropy (ΔS) values and were strongly exothermic. A negative ΔS value suggests that the system becomes more ordered upon binding, resulting in a complex with restricted mobility during the interaction. At the same time, the exothermic binding is indicative of the release of heat to the environment, which is likely facilitated by hydrogen bonding and van der Waals forces rather than hydrophobic effects. Furthermore, all derivatives have negative ΔG values when bound to haemin, suggesting that binding is both spontaneous and thermodynamically favourable. Overall, the findings support the haemin binding potential of the curcumin derivatives, suggesting their potential as multi-target antimalarials. Experimental In-silico assessments ADMET studies The predicted ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of curcumin, which we have previously obtained from the SwissADME (http://www.swissadme.ch/index.php), pkCSM (http://biosig.unimelb.edu.au/pkcsm/), and proTox-II (https://tox.charite.de/protox_II) web servers, were compared to those of the derivatives19,53–55. The ADMET information predicts the overall pharmacological behaviour of potential drug candidates in the body, including the blood, tissues, and organs, thus providing an alternative pathway for screening a long list of compounds. Molecular docking The 3D X-ray crystallographic structure of GSK-3β was retrieved from the Protein Data Bank (PDB ID: 1Q5K, resolution 1.94 Å, https://www.rcsb.org)25. It was prepared for molecular docking by removing water molecules and adding polar hydrogen as well as Kollman charges, before being saved as a.pdbqt file56. The docking analysis was performed to screen curcumin derivatives that bind best to GSK-3β while determining the optimal energy geometry of the docked compounds. Based on the previously validated active site of the protein, the docking simulation was performed with a defined grid box dimension of 40 × 30 × 30 Å centred at x = 23.9226, y = 21.6961, and z = 9.7608156,57. The active site of the protein is specified as the cavity that binds specific ligands (curcumin derivatives), resulting in potential inhibition of its activity. The other docking parameters were set to default57. Analysis of the docking results revealed the binding affinity, the type of molecular interactions and the amino acids involved in the binding. BIOVIA Discovery Studio Visualizer58 and Ligplot+59 were utilised to map the interactions and visualise the position and distance of the amino acid residues interacting with the ligands. MD simulations MD simulations were performed to analyse the dynamics of ligand-protein complexation and to validate the docking results. In an MD simulation, the environment of the system mimics the biological system for the behaviour and stability of the bound ligand and protein, while allowing conformational changes of the ligand within the active site of the protein26. The simulations were carried out over 100 ns using the GROMACS 2020.6 software package60 running on a Ubuntu − 2020.6-2.6 operating system to generate information on root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), and hydrogen bond interactions. The temperature and pressure for the experimental conditions were set at 300 K and 1 atm, respectively, to imitate the physiological61. DFT calculations DFT calculations were performed using GaussView 6.0.1662 at the B3LYP/6-311G++(d, p) level, which was adopted from the previously reported method by Hazarika and Kalita40. The DFT analysis provides critical information on energy minimisation for bonding, dipole moment, molecular orbital energy profile and the global reactivity parameters from geometry optimisation calculations. Theoretically, it enables geometry optimisation of a chemical structure in order to find its stable geometry using a quantum chemical technique63. Synthesis of Curcumin derivatives Materials Curcumin was purchased from Sigma Aldrich Co. (USA) (> 80% purity) and Tokyo Chemical Industry (TCI) (Japan) (synthetic, > 97% purity). Other chemicals were purchased: R-benzaldehyde and R-phenylhydrazine hydrochloride from Sigma Aldrich Co. (USA), solvents from Merck (Germany) and other commercial sources. All purchased reagents and chemicals were used without further purification. TLC plates (Kieselgel 60 F254) from Merck (Germany) were used and visualised with ultraviolet (UV) light at 254 nm. Flash column chromatography for purification was performed with Merck silica gel 60 (0.04–0.063 mm). Instrumentations and compound characterisations All the synthesised compounds were characterised and identified by Nuclear Magnetic Resonance (NMR) spectroscopy. Samples were dissolved in deuterated chloroform, CDCl3, measured using Bruker Fourier Transform FT-NMR (400 MHz) (Karlsruhe, Germany) available in the i-CRIM laboratory, Universiti Kebangsaan Malaysia (UKM) or JEOL JNM-ECS-400 spectrometer (Japan) available at the Graduate School of Engineering, Gifu University, Japan and analysed using ACD/Labs NMR Processor software with chemical shifts (δ) reported in parts per million (ppm). Multiplicity is designated as follows: s = singlet, d = doublet, t = triplet, q = quartet, br = broad, dd = doublet of doublet, dt = doublet of triplet, ddd = doublet of doublet of doublet, m = multiplet. NMR data were analysed, and all spectra were matched with the previously reported information. Characterisation details of all synthesised compounds, including 1H and 13C NMR spectroscopy, can be found within the Supporting Information. Synthesis of Knoevenagel condensate Curcumin derivatives The synthesis was conducted by reacting curcumin (0.543 mmol, 1.00 eq.) with appropriate R-benzaldehyde (0.706 mmol, 1.30 eq.) in 1.00 mL dry DMF, catalysed by piperidine (0.543 mmol, 1.00 eq.) and acetic acid (0.706 mmol, 1.30 eq.) at RT for 48 h. On completion (monitored by TLC), the reaction mixture was diluted with ethyl acetate and washed with water, followed by brine. Purified yield was obtained by column chromatography using a gradient eluent system (Hexane: EtOAc = 100:0 → 60:40, v/v) and dried under reduced pressure. Purified compounds were characterised and validated by 1H NMR and compared with the previously published data20,42. Synthesis of heterocyclic pyrazole Curcumin derivatives The synthesis was conducted by reacting curcumin (0.271 mmol, 1.00 eq.) with R-phenylhydrazine hydrochloride (0.407 mmol, 1.50 eq.) in 4.00 mL ethanol, catalysed by acetic acid (5.24 mmol), reflux at 85 °C, for 15 h. On completion (monitored by TLC), the crude was dried under reduced pressure, followed by a treatment with ethyl acetate. Solid precipitate was filtered and washed with cold water. Final yield was left drying in a desiccator for 24 h to obtain the purified yield. Purified compounds were characterised and validated by 1H NMR and compared with the previously published data64. Synthesis of monocarbonyl Curcumin derivatives A mixture of vanillin (0.657 mmol, 2.00 eq.) and an appropriate ketone (0.328 mmol, 1.00 eq.) was reacted in 1.00 mL acetic acid, catalysed by concentrated hydrochloric acid (0.328 mmol, 1.00 eq.) at 30 °C for 2 h. After completion (monitored by TLC), the reaction mixture was left standing for 24 h before the crude was filtered and washed with cold water. The product was redissolved with ethyl acetate and washed from water. The organic layer was collected and purified yield was dried under reduced pressure. Purified compounds were characterised and validated by 1H NMR and compared with the previously published data45,46. Biological assessments In vitro P. falciparum 3D7 and K1 assays Antiplasmodial activities were assessed using the P. falciparum CQ-sensitive 3D7 and multidrug-resistant K1 strains, obtained from the Malaria Research and Reference Reagent Resource Center (MR4), Manassas, Virginia. The parasites were revived from cryopreservation and cultured at 1% haematocrit using purified O + human erythrocytes in RPMI 1640 medium supplemented with 0.5% Albumax I (GIBCO, Life Technologies, USA), 25 mM HEPES, 100 µM hypoxanthine, 12.5 µg/mL gentamicin, and 1.77 mM sodium bicarbonate. Cultures were retained at 37 °C in 5% CO₂ atmosphere. Parasitaemia level was assessed by microscopically examining the field-stained thin blood smears. Parasite sensitivity to the compounds was evaluated using the parasite lactate dehydrogenase (pLDH) assay in flat-bottom 96-well microtiter plates65. Before the assay was performed, parasite cultures were synchronised using 5% D-sorbitol and plated at 2% haematocrit and 2% parasitaemia, predominantly in the ring stage. Curcumin derivatives were added at the predetermined concentrations. After one hour of incubation at RT with no visible light, colour development was measured at 655 nm using a Fluostar Optima microplate reader. GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA) was utilised to determine the 50% effective concentration (EC₅₀) via non-linear regression. MTT cytotoxicity assay Normal human liver cell line WRL-68 (ATCC: CL-48) was obtained from the American Type Culture Collection (ATCC), USA. Cytotoxicity of curcumin derivatives was assessed using the MTT assay, as described by Mosmann66. Briefly, 100 µL of WRL-68 cells (2 × 10⁴ cells/mL) in complete medium supplemented with 10% foetal bovine serum (FBS) was seeded into 96-well flat-bottom microtiter plates. Cells were incubated in the presence/absence of the assessed compounds for 48 h at 37 °C in a 5% CO₂ atmosphere. After incubation, confluent cells were treated with curcumin derivatives at concentrations ranging from 10 to 0.01 µg/mL. Wells containing untreated cells served as positive controls for cell viability. Following treatment, 5 mg/mL MTT solution in phosphate-buffered saline (MTT-PBS) was added to each well, and the plates were incubated for an additional 3 h under the same conditions. The medium was then removed and replaced with 100 µL of dimethyl sulfoxide (DMSO) per well to solubilise the formazan crystals, followed by a 10-minute incubation at 37 °C in a CO₂ incubator. Absorbance was measured at 540 nm using a Fluorostar OPTIMA microplate reader. The 50% cytotoxic concentration (CC₅₀) of the curcumin derivatives was determined from three independent experiments. Percentage growth inhibition and CC₅₀ values were calculated by non-linear regression analysis using GraphPad Prism. Cytotoxicity was reported as the concentration required to inhibit 50% of cell growth. Selectivity index (SI) and resistance index (RI) The selectivity index (SI) was calculated as the ratio of the 50% cytotoxic concentration (CC₅₀) to the 50% inhibitory concentration (IC₅₀) of antimalarial activity (SI = CC₅₀/IC₅₀), based on data from MTT and pLDH assays. Compounds with SI values greater than 100 (SI > 100) were considered strong and selective antiplasmodial agents, as described by Sarr et al.67. Additionally, the resistance index (RI) was determined by calculating the ratio of IC₅₀ values obtained from the resistant strain (K1) to those from the sensitive strain (3D7) (RI = IC₅₀ K1/IC₅₀ 3D7). A higher RI indicates reduced sensitivity of the resistant strain to the test compound. In vitro yeast-based GSK-3β assay The GSK3β-inhibitory activity of test compounds was assessed using a yeast-based assay as described by Andoh et al.69. In this system, mammalian GSK3β was inserted and expressed in a temperature-sensitive gsk-3 null mutant yeast strain (pKT10-GSK3β) with the genotype MATa his3 leu2 ura3 trp1 ade2 mck1::TRP1 mds1::HIS3 mrk1 yol128c::LEU2, thereby restoring the original phenotype. For screening, a loopful of a three-day-old yeast culture was inoculated into 5.0 mL of synthetic complete medium lacking uracil (SC-Ura) and incubated in a water bath at 37 °C with shaking at 150 rpm for 48 h. Subsequently, 400 µL of the yeast culture was mixed with 100 mL of SC-Ura agar, poured into six plates, and allowed to solidify at RT. The disc diffusion technique was employed by applying 20 µL of 100 mg/mL test samples onto sterile paper discs, which were then placed on the SC-Ura agar plates. Plates were incubated at both 28 °C (permissive temperature) and 37 °C (restrictive temperature) for 120 h, and yeast growth was monitored over five days. All assays were conducted in triplicate. Inhibition of yeast growth at 37 °C indicated GSK3β-inhibitory activity of the test compounds56,70. ITC experiments An ITC microcalorimeter (TA Instruments, New Castle, DE, USA) was utilised to assess the interaction of the synthesised curcumin derivatives with haemin at 37 °C as described by Feroz et al.68. Curcumin and CQ were used as reference compounds to enable comparative analysis of binding affinities and thermodynamic parameters. The synthesised compounds were dissolved in acetone at concentrations ranging from 1 to 1.5 mg/mL to prepare stock solutions, while the haemin stock solution (0.5 mg/mL) was prepared by dissolving haemin in 0.5 M NaOH. The stock solutions were subsequently diluted with 10 mM sodium phosphate buffer (pH 7.4), resulting in the final samples containing 0.5 M NaOH and about 3% acetone. All samples were vacuum-degassed for 10 min before the titration experiments. For the titration, 20 µM haemin was placed in the sample cell, with the reference cell containing deionised water. The derivative compound (100 µM) was loaded into a 250 µL syringe and introduced into the microcalorimeter for injection. The titration required 16 consecutive 15 µL injections into the sample cell, spaced each 400 s intervals, with stirring kept at 200 rpm to ensure adequate mixing. Before data analysis, the heat effects from solution mixing and dilution were manually corrected. An independent binding model was employed to analyse the data using NanoAnalyze software (v3.3.0). The results are presented as the average ± standard deviation of selected replicates showing the best consistency. Conclusion The present findings demonstrate that the assessed curcumin derivatives generally exhibited favourable immunomodulatory GSK-3β inhibitory potential, physicochemical properties, and DFT profiles. Biological evaluations confirmed their promising antimalarial potential compared to curcumin 1. The pLDH assays verified that all derivatives demonstrated more potent antiplasmodial activity against both 3D7 and K1 strains than curcumin, with the monocarbonyl derivative 20 being the most potent. Additionally, ITC experiments indicated the potential of these derivatives to disrupt hemozoin formation in the haemin detoxification pathway of Plasmodium, based on their favourable and spontaneous haemin binding. Moreover, the in vitro yeast-based study showed that derivative 20, with favourable pharmacokinetics profile, demonstrated capacity for selective GSK-3β inhibition. The overall results exemplify improved bioactivity of curcumin derivatives. However, observations from the in vitro yeast-based assay showed limited measurable GSK-3β inhibition, highlighting the constraints of yeast-based applications for exploring and validating potential GSK-3β inhibition, particularly for compounds with extended frameworks and larger molecular weights. Therefore, employing mammalian GSK-3β expressing assays, along with further scaffold derivatisations, in vivo assessments, pharmacokinetic studies, and mechanism-focused investigations, would be valuable in gaining a comprehensive understanding of the antimalarial potential of curcumin derivatives, thereby advancing the discovery and development of potent antimalarials. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements This study was supported by grants from Universiti Kebangsaan Malaysia [DIP-2024-006] and the South Asia Research Hub, Foreign, Commonwealth & Development Office (FCDO), Government of the United Kingdom [ST-2024-001]. The views expressed in this report, however, do not necessarily reflect the official policies of the Government of the United Kingdom. The authors also acknowledge financial assistance awarded to SNHJ by the Graduate School of Engineering under the International Joint Department of Materials Science and Engineering between Universiti Kebangsaan Malaysia and Gifu University, and Majlis Amanah Rakyat (MARA) under the Graduate Excellence Programme (GREP). We would also like to sincerely thank the members of the Malaria Culture Laboratory, Department of Parasitology, Faculty of Medicine, Universiti Malaya for their support. Author contributions SNHJ contributed to conceptualisation, methodology planning, data curation, formal analysis, writing, reviewing and editing the original draft. KAB, AHA, NFNM and FS were involved in conceptualisation, methodology planning, writing, reviewing and editing the original draft. FM, SDL and SRF were involved in conceptualisation, methodology planning, reviewing and editing the draft, providing resources and access to software, supervising the progress, and data validation. NO provided supervision, reviewing and editing the manuscript. YZ, MIM, RM and US provided access to resources and supervised the progress. JL contributed to funding acquisition, project administration, access to resources, and overall supervision. All authors reviewed the manuscript. Funding This study was supported by the South Asia Research Hub, Foreign, Commonwealth & Development Office (FCDO), Government of the United Kingdom [ST-2024-001]. Data availability All data generated or analysed during this study are included in this published article and its supplementary information files. Declarations Ethics approval and consent to participate Clinical trial number: not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement All data generated or analysed during this study are included in this published article and its supplementary information files.